The median survival of patients with chronic phase of chronic granulocytic leukemia is 39-47 months, and they enter the end stage of acute phase in 3-5 years, and a few chronic phase can extend for 10-20 years.
Chronic myeloid leukemia, commonly known as slow granulomas. Its natural course can be divided into chronic, accelerated and acute phase. Molecularly targeted agents tyrosine kinase inhibitors (e.g., imatinib mesylate, nilotinib, and dasatinib) specifically inhibit the proliferation of BCR-ABL-positive cells, and have become available options for first-line treatment regimens.
The prognosis of chronic myeloid leukemia is related to the risk assessment at the time of diagnosis, the way the disease is treated, and the evolution of the disease. Since the use of tyrosine kinase inhibitors, patient survival has been significantly prolonged. Specific diagnosis and treatment should be directed by a physician.